HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Nuvation Bio (NYSE:NUVB) and maintained a price target of $8.
May 22, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Nuvation Bio and maintained a price target of $8, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100